ARBs Raise Renin and Can Cause False-Negative ARR Results
ARBs (angiotensin-II receptor blockers) significantly elevate renin levels, which lowers the aldosterone-to-renin ratio (ARR) and can lead to false-negative screening results for primary aldosteronism. 122
Mechanism of Interference
ARBs block the angiotensin-II receptor, which triggers a compensatory increase in renin secretion. This renin elevation artificially lowers the ARR by increasing the denominator of the ratio, potentially masking primary aldosteronism even when aldosterone levels remain inappropriately elevated 22.
Clinical Implications for ARR Interpretation
When ARBs Are Present During Screening:
- A detectable renin level or low ARR does NOT exclude primary aldosteronism in patients on ARBs 22
- However, if renin remains undetectable despite ARB therapy, primary aldosteronism is strongly suspected 22
- This creates a unique interpretive scenario where suppressed renin on an ARB is highly specific for PA
Guideline Recommendations for ARB Management:
Withdraw ARBs for at least 2 weeks before ARR testing when feasible and safe 122. The 2025 Endocrine Society guideline specifically states this 2-week washout period for both ACE inhibitors and ARBs 1.
Practical Algorithm for ARB Management
For initial screening:
- Discontinuation of ARBs is not strictly required if it would compromise blood pressure control 22
- You can proceed with screening while on ARBs, but interpret results cautiously
If screening is negative while on ARBs:
- Repeat testing after withdrawing ARBs for 2 weeks if the patient has moderate-to-high pretest probability (resistant hypertension, hypokalemia) 1
- This is particularly important if renin is detectable but aldosterone is 5-10 ng/dL 1
Alternative antihypertensives during washout:
- Use alpha-1 blockers (doxazosin), hydralazine, or non-dihydropyridine calcium channel blockers (verapamil, diltiazem) 22
- These medications minimally affect the renin-aldosterone axis
Critical Pitfall to Avoid
The most common error is accepting a negative ARR result in a patient with high clinical suspicion (resistant hypertension, hypokalemia) who remains on ARBs. Always repeat testing after appropriate medication adjustment in these cases 1. The renin-raising effect of ARBs can completely obscure the diagnosis, particularly in patients with milder forms of primary aldosteronism where aldosterone levels may not be dramatically elevated 3.
Contrast with Beta-Blockers
Unlike ARBs which raise renin, beta-blockers suppress renin and can cause false-positive results by artificially elevating the ARR 12. This creates the opposite problem and requires different management strategies.